Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 248

Sort by

Sort Order Select

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch

Blood (2023) 142 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2023-181871

Published: 2023

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Ivory Tang, Yanis Tazi, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Hartmut Dohner, Brian Huntly, Nigel H. Russell, Sanam Loghavi, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 818.

https://doi.org/10.1182/blood-2023-179598

Published: 2023

Journal Articles

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Blood (2023) 142 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2023-185566

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Rabea Mecklenbrauck, Nora Borchert, Piroska Klement, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas Thol, Michael Heuser

Blood (2023) 142 (Supplement 1): 817.

https://doi.org/10.1182/blood-2023-179412

Published: 2023

Journal Articles

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2023) 142 (Supplement 1): 619.

https://doi.org/10.1182/blood-2023-173225

Published: 2023

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Blood (2022) 140 (Supplement 1): 6293–6294.

https://doi.org/10.1182/blood-2022-159212

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo

Fiorella Charles Cano, Arnold Kloos, Rucha Yeshwanta Hebalkar, Razif Gabdoulline, Thomas Fangmann, Yosef Landesman, Konstanze Döhner, Halyna R. Shcherbata, Arnold Ganser, Michael Heuser

Blood (2022) 140 (Supplement 1): 4938–4939.

https://doi.org/10.1182/blood-2022-155836

Published: 2022

Journal Articles

Wnt and Notch Pathways Regulate Stemness of Myeloid Leukemia Cells Via IL33/ST2 Signaling

Pascal Naef, Ramin Radpour, Carla Jaeger-Ruckstuhl, Nils Bodmer, Gabriela M Baerlocher, Hartmut Döhner, Konstanze Döhner, Carsten Riether, Adrian Ochsenbein

Blood (2022) 140 (Supplement 1): 2986–2987.

https://doi.org/10.1182/blood-2022-164810

Published: 2022

Journal Articles

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Griesshammer, Konstanze Döhner, Steffen Koschmieder

Blood (2022) 140 (Supplement 1): 6874–6876.

https://doi.org/10.1182/blood-2022-165034

Published: 2022

Journal Articles

Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Blood (2022) 140 (Supplement 1): 6070–6072.

https://doi.org/10.1182/blood-2022-163035

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Rabea Mecklenbrauck, Nora Borchert, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Piroska Klement, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Andreas Voss, Michael Lübbert, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas R. Thol, Michael Heuser

Blood (2022) 140 (Supplement 1): 6254–6255.

https://doi.org/10.1182/blood-2022-162725

Published: 2022

NARROW

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo

Wnt and Notch Pathways Regulate Stemness of Myeloid Leukemia Cells Via IL33/ST2 Signaling

Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)

Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only